ABCANN GLOBAL CORPORATION (CVE:ABCN) with its aggressive expansion plans and healthy cash position, is one firm seeking to address supply concerns, especially in the medicinal market. Joined in the sector by Aurora Cannabis Inc. (OTCMKTS:ACBFF), Canopy Growth Corporation (OTCMKTS:TWMJF), Medical Marijuana Inc (OTCMKTS:MJNA) and Aphria Inc.(OTCMKTS:APHQF), ABcann’s relatively low market capitalization and beefy portfolio of pharma-grade IP have it on the scale of investors seeking to capitalize on Canada’s much-expected “green” revolution.
NetworkNewsWire Editorial Coverage reported that the Canadian government’s strategy to push through marijuana legalization for recreational purposes by mid-2018 figures to fix a serious blow to the current black market. However, industry experts are increasingly doubtful of the ability of the nation’s Licensed Producers to sustain pace with this expected spike in demand.
As mentioned in a recent article released by CBC, unless something changes rapidly, the supply of available marijuana come legalization in July 2018, will be inadequate, and the black market will sustain to thrive.
Just months out from its IPO, ABcann Global has already demonstrated remarkable potential in distinguishing itself from other Canadian cultivators. The backbone of the firm’s operations, which focus on the advancement of consistent pharmaceutical-grade offerings that are pesticide-free and organically grown, is its proprietary cultivation technology.
As mentioned on its website, ABcann’s offerings are produced in small batches and always free of chemicals to achieve high quality standards. This assurance to quality has helped company steer clear of the latest wave of product recalls in the cannabis market in Canada that has impacted several biggest names.
Scaling these businesses has become a prime focus for ABcann’s management team in latest months, as highlighted by the firm’s latest strategic moves. In mid-September, the company reported total proceeds of $11.9 million from the exercise of warrants. Together with another investment from cannabis streaming firm Cannabis Wheaton Income Corp., the cash infusion resulted in ABcann’s cash position to come at around $45 million.